The ATP-Gated P2X1 Ion Channel Acts as a Positive Regulator of Platelet Responses to Collagen

ATP is a potent agonist of the P2X1 ion channel, mediating a rapid, quickly desensitized influx of Ca2+. In hirudinized PRP, containing apyrase, the two stable selective P2X1 agonists, alpha,beta-methylene ATP, and L-beta,gamma-methylene ATP induced extracellular Ca2+-dependent fast and reversible platelet shape change, leading to desensitization of the P2X1 ion channel. Preincubation with HPLC-purified ADP potently antagonized the subsequent alpha,beta-methylene ATP- and L-beta,gamma-methylene ATP-evoked platelet shape change. Accordingly, upon heterologous expression of P2X1 in Xenopus oocytes. HPLC-purified ADP acted as an antagonist of the ATP-induced current, but was inactive itself. Since ATP and ADP are co-released from dense granules during platelet activation, we investigated whether the P2X1 ion channel is involved in the response of platelets to collagen. We found that platelet shape change and aggregation induced by low concentrations of collagen were strongly inhibited after selective desensitization of P2X1 with its agonists or by pretreating the platelets with a low concentration of ADP (0.5 microM), that antagonizes the P2X1 channel without desensitizing the P2Y1 receptor. Our data suggest that, during collagen-initiated platelet activation, the early secretion of ATP results in the activation of the P2X1 ion channel, which plays a role as a positive regulator of further platelet responses.

[1]  C. Brearley,et al.  Platelet Shape Change Evoked by Selective Activation of P2X1 Purinoceptors with α,β-Methylene ATP , 2001, Thrombosis and Haemostasis.

[2]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[3]  C. Brearley,et al.  Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. , 2001, Thrombosis and haemostasis.

[4]  J. Herbert,et al.  FcγRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation , 2000 .

[5]  S. Offermanns,et al.  ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. , 2000, Blood.

[6]  R. Evans,et al.  ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets , 2000, British journal of pharmacology.

[7]  R. Storey,et al.  The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity , 2000, British journal of haematology.

[8]  J. Cazenave,et al.  Desensitization of the Platelet Aggregation Response to ADP: Differential Down-regulation of the P2Y1 and P2cyc Receptors , 2000, Thrombosis and Haemostasis.

[9]  J. Heemskerk,et al.  The roles of P(2X1)and P(2T AC)receptors in ADP-evoked calcium signalling in human platelets. , 2000, Cell calcium.

[10]  J. Vermylen,et al.  A Natural Dominant Negative P2X1 Receptor Due to Deletion of a Single Amino Acid Residue* , 2000, The Journal of Biological Chemistry.

[11]  J P Cazenave,et al.  Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. , 1999, The Journal of clinical investigation.

[12]  B. Payrastre,et al.  A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. , 1999, Blood.

[13]  ChristianGachet,et al.  ADP Receptors and Clinical Bleeding Disorders , 1999 .

[14]  Beverly H. Koller,et al.  Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice , 1999, Nature Medicine.

[15]  M. Aepfelbacher,et al.  Dichotomous Regulation of Myosin Phosphorylation and Shape Change by Rho-Kinase and Calcium in Intact Human Platelets , 1999 .

[16]  S. Watson.  Collagen Receptor Signaling in Platelets and Megakaryocytes , 1999, Thrombosis and Haemostasis.

[17]  J. Kimura,et al.  No requirement of P2X1 purinoceptors for platelet aggregation. , 1999, European journal of pharmacology.

[18]  A. Bailey,et al.  Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. , 1999, Journal of medicinal chemistry.

[19]  G. Dubyak,et al.  Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase , 1998 .

[20]  S. Kunapuli,et al.  Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. J. Robertson,et al.  P2Y1‐receptors in human platelets which are pharmacologically distinct from P2YADP‐receptors , 1998, British journal of pharmacology.

[22]  S. Kunapuli,et al.  Molecular Basis for ADP-induced Platelet Activation , 1998, The Journal of Biological Chemistry.

[23]  J. Herbert,et al.  Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel , 1997, British journal of haematology.

[24]  P. Ohlmann,et al.  Activation of ADP Receptors and Platelet Function , 1997, Thrombosis and Haemostasis.

[25]  P. Mannucci,et al.  Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production , 1997, Thrombosis and Haemostasis.

[26]  J. Cazenave,et al.  The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells , 1997, FEBS letters.

[27]  R. North,et al.  Domains of P2X receptors involved in desensitization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Mills,et al.  ADP Receptors on Platelets , 1996, Thrombosis and Haemostasis.

[29]  A. Mackenzie,et al.  Activation of Receptor-operated Cation Channels via P Not P Purinoceptors in Human Platelets (*) , 1996, The Journal of Biological Chemistry.

[30]  R. North,et al.  Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). , 1995, Molecular pharmacology.

[31]  P. Stanssens,et al.  An echistatin‐like Arg‐Gly‐Asp (RGD)‐containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function , 1994, British journal of haematology.

[32]  S. Hourani,et al.  Effects of analogues of adenine nucleotides on increases in intracellular calcium mediated by P2T‐purinoceptors on human blood platelets , 1993, British journal of pharmacology.

[33]  J. Hubbell,et al.  ADP Receptor Antagonists and Converting Enzyme Systems Reduce Platelet Deposition onto Collagen , 1992, Thrombosis and Haemostasis.

[34]  C. Cimminiello,et al.  Ticlopidine Selectively Inhibits Human Platelet Responses to Adenosine Diphosphate , 1991, Thrombosis and Haemostasis.

[35]  P. Mannucci,et al.  Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. , 1990, Blood.

[36]  R. Malmgren.  ATP-secretion occurs as an initial response in collagen induced platelet activation. , 1986, Thrombosis research.

[37]  H. Reimers.  4 – Adenine Nucleotides in Blood Platelets , 1985 .

[38]  S. Hourani,et al.  ADENOSINE 5′‐DIPHOSPHATE ANTAGONISTS AND HUMAN PLATELETS: NO EVIDENCE THAT AGGREGATION AND INHIBITION OF STIMULATED ADENYLATE CYCLASE ARE MEDIATED BY DIFFERENT RECEPTORS , 1982, British journal of pharmacology.

[39]  H. Weiss,et al.  Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha- granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor , 1979 .

[40]  Kaplan,et al.  Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. , 1979, Blood.